Bauman Medical’s aHFS versus PRP announcement reports laboratory differences and preliminary skin findings, not proof of better hair regrowth.
On September 24, 2026, Bauman Medical announced that an abstract by Alan J. Bauman comparing autologous hair-follicle secretome with platelet-rich plasma had been accepted for an oral presentation. The announcement outlined a laboratory comparison alongside preliminary findings about skin recovery after laser treatment.
The society’s congress announcement placed the International Society of Hair Restoration Surgery’s 34th World Congress in Rio de Janeiro, with dates scheduled for October 15 to 17. Bauman Medical described a five-minute presentation in the General Session.
The announcement brings an emerging approach into view. Its significance depends on understanding exactly what was compared and which questions remain open.
In Bauman Medical’s announcement, the company describes autologous hair-follicle secretome, abbreviated aHFS, as a cell-free formulation. It says the material comes from a patient’s own hair follicle stem cells and mesenchymal stem cells. The company identifies a patented expansion method developed by Acorn Biolabs as part of its production process.
“Autologous” refers to the patient being the source of the starting material. “Cell-free” describes the resulting formulation rather than the cells used to produce it. Keeping those terms separate helps clarify what the company is proposing.
The announced comparison examined aHFS alongside platelet-rich plasma, or PRP, prepared from the same donors using double-spin centrifugation. Bauman Medical says the analysis profiled 37 regenerative molecules. The methods listed were mass spectrometry, multiplex ELISA and nanoparticle tracking analysis.
That makes the comparison primarily a characterization of the materials. Its central question was what the samples contained and how their measured components differed. The fact that samples came from the same donors is part of the reported design, not a description of a patient treatment comparison.
Bauman Medical reported higher concentrations of selected components in aHFS than in PRP. Its announcement highlighted these laboratory findings:
The wording matters. These were selected measurements, and “up to” identifies the upper reported comparison rather than a uniform difference across all components. The figures describe concentrations rather than a percentage improvement in hair growth.
The announcement also reported an average of five billion exosome particles per aHFS sample. It listed a modal particle size of 137 nanometers and protein content of approximately 14 mg/mL. These measurements add detail about the formulation being characterized.
Separately, Bauman Medical described a preliminary study involving 11 participants recovering from ablative laser treatment. The company reported a 39% improvement in cosmetic appearance and a 63% improvement in skin “feel.” Those percentages belong to the reported skin-recovery study and should remain attached to that setting.
For routine-care relevance, the important question is how patients do over time. Laboratory measurements and preliminary study percentages answer narrower questions than a dependable estimate of what someone will experience in clinical practice.
The central evidence limitation is the nature of the publication. These findings were reported in a company-distributed announcement rather than presented as independently verified conclusions in a peer-reviewed paper. Acceptance for a congress presentation is a different milestone from publication of a complete clinical study.
The announcement does not report clinical hair-growth outcomes such as hair counts, density measurements or patient regrowth results. Higher concentrations of selected molecules therefore do not establish that aHFS restores more hair than PRP. A biochemical difference needs a clinical test before it can support a claim of superior effectiveness.
The skin-recovery findings have their own boundaries. Beyond the small preliminary sample, the release does not provide the full protocol, statistical analysis, follow-up duration or detailed comparator information. Results after ablative laser treatment also do not establish effectiveness for other skin procedures or populations.
Bauman Medical says longer-term efficacy data are being gathered in an ongoing multicenter observational trial identified as NCT06477172. The announcement does not report that trial’s results. Describing ongoing research is not the same as supplying its findings.
The release also disclosed Bauman’s researcher relationship with Congela Biosciences and ownership interest in HairScience LLC. These relationships are relevant context when assessing company-reported findings. They do not determine whether the measurements are sound, but they belong alongside the claims.
Finally, the company describes aHFS as investigational and says it is not cleared or approved by the U.S. Food and Drug Administration. The release also says the presentation would disclose investigational or off-label use. Conference acceptance should not be read as regulatory authorization.
For someone considering hair-loss care, the useful response is to focus on the next layer of evidence rather than on the largest laboratory number. A future report would be more informative if it made the patient outcomes and study design clear.
Questions worth bringing to new publications include:
These are questions for evaluating evidence, not instructions for choosing a procedure. Decisions about personal hair-loss care belong with a qualified clinician who can discuss the individual situation and the status of a proposed treatment.
For related research context, Younell covers early-stage hair-loss findings alongside later-stage clinical data. Reading across different stages of research helps keep attention on the outcomes being measured rather than the novelty of the approach.
The useful question now is whether the reported biological differences translate into a meaningful benefit for patients. Answering it will require clearly reported clinical outcomes with enough detail to assess the comparison.
Bauman Medical’s announcement offers a description of an investigational formulation and the measurements behind its proposed presentation. The next meaningful advance would be evidence connecting those measurements to sustained patient outcomes. That is the point at which the discussion can move from what the material contains to how well it performs.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
